Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$0.86
-$0.01(-1.50%)
At close: 4:00 PM EDT
$0.86
-$0.01(-1.50%)
Day’s Range― - ―
52-Week Range$0.73 - $1.51
Previous CloseN/A
Volume317.18K
Average Volume (3M)808.03K
Market Cap
$98.03M
Enterprise Value$110.07
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Oct 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding127,510,506
10 Day Avg. Volume1,182,502
30 Day Avg. Volume808,034
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside481.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway ProgressFDA alignment on REO 033 provides a clearer development and registration framework for pelareorep in RAS-mutant metastatic colorectal cancer. The potential to use response and survival endpoints within an expansion program could improve development efficiency, although execution remains dependent on supportive trial data.
Durable Intellectual PropertyPatent protection covering pelareorep’s commercial manufacturing process through 2044 can support exclusivity if the therapy reaches commercialization. The broader layered strategy across manufacturing, use, formulation, and combinations may strengthen the company’s competitive position across multiple oncology indications.
Combination Therapy PotentialThe preclinical combination findings support a biologically coherent strategy for pairing pelareorep with RAS-targeted therapies. Preserved activity without antagonism creates a basis for further dosing and resistance-focused studies, potentially expanding pelareorep’s relevance in gastrointestinal cancers if clinical results confirm the effect.
Bears Say
Pre-revenue And Widening LossesThe company remains pre-revenue while operating and net losses continue to expand, indicating that its clinical development model has not yet produced commercial income. This places fundamental value on future trial and regulatory success and leaves earnings power dependent on eventual approvals or partnering outcomes.
Persistent Cash BurnSustained negative operating and free cash flow shows that ongoing research and development require substantial external funding. The increased burn versus 2025 may reduce the time available to reach important clinical milestones and could require additional capital before the business can generate recurring operating cash.
Balance-sheet DeteriorationNegative equity and the sharp reduction in total assets indicate materially weaker financial flexibility than in prior years. Although absolute debt is low, the deteriorated balance sheet provides a smaller cushion for continued operations and increases reliance on external financing while clinical programs advance.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.73 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $98.03M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Oct 30, 2026 which is in 41 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 12, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.025.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.05.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 127,510,506 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went down -2.795%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (481.40% Upside)
$5.00 (481.40% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average 62%
Sector Average 62%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.5%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$5.00
▲(481.40% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―